To include your compound in the COVID-19 Resource Center, submit it here.

OBI-1: Interim Phase III data

Interim data from 3 patients with serious bleeding episodes that were not controlled with NovoSeven or Feiba VH in the open-label, Phase

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE